Drug-Patent Cliffs
Invest in

Drug-Patent Cliffs

41.9%
6.3%
0.4%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
41.9%
6.3%
0.4%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
62.7% Generic Drugs 29.8%
19.7% Perrigo Co. PRGO 24.6%
11.8% Mylan NV MYL --
7.5% Dr. Reddys Laboratories Ltd. ADS RDY 32.9%
5.5% Taro Pharmaceutical Industries Ltd. TARO 1.0%
4.6% Akorn Inc. AKRX 35.6%
4.1% Mallinckrodt plc MNK 73.9%
2.9% Impax Laboratories Inc. IPXL 107.3%
2.0% Sagent Pharmaceuticals Inc. SGNT 1.0%
1.6% Igi Laboratories Inc IG 64.4%
1.2% Cambrex Corp. CBM 113.1%
1.1% Amphastar Pharmaceuticals Inc (DE) AMPH 81.0%
0.9% Lannett Co. Inc. LCI 56.6%
31.9% Big Pharma 32.9%
27.6% Teva Pharmaceutical Industries TEVA 34.6%
4.3% Abbott Laboratories ABT 21.6%
5.4% Biosimilars 104.4%
1.5% Coherus BioSciences Inc CHRS --
1.5% Pfenex Inc PFNX 291.5%
1.4% Momenta Pharmaceuticals Inc. MNTA 104.7%
1.0% EPIRUS Biopharmaceuticals Inc EPRS 16.5%